

# BC Cancer Protocol Summary for Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide

**Protocol Code:** *BRLACPNA*

**Tumour Group:** *Breast*

**Contact Physician:** *Dr. Angela Chan*

## ELIGIBILITY:

Patients must have:

- Previous severe hypersensitivity reaction or anaphylaxis to PACLitaxel that is not manageable despite use of premedications, or
- Previous moderate PACLitaxel hypersensitivity reaction that cannot be managed by premedications due to a strong contraindication to high dose steroids, such as poorly controlled diabetes, and
- **Triple negative breast cancer\***, previously treated with curative intent breast cancer protocol BRLACTWAC

\* Patients are eligible if:

1. HER2 negative:

- HER2 IHC 0 to 1, or
- HER2 IHC 2 with FISH negative, and

2. ER negative:

- Less than 1% of ER positive cells, and
- ER Allred score 0 to 2 out of 8
- **Regardless of PR results**
- **All other cases including ER-low requests require approval via BC Cancer Compassionate Access Program (CAP)**

Patients should have:

- Adequate hematological, renal and hepatic function

## EXCLUSIONS:

Patients must not have:

- Severe cardiovascular disease with LVEF less than 45%
- Severe hepatic dysfunction contraindicating PACLitaxel NAB (ABRAXANE) or DOXOrubicin

**CAUTIONS:**

- Greater than or equal to grade 2 sensory or motor neuropathy

**TESTS:**

- Baseline: CBC & diff, platelets, bilirubin, ALT, GGT, LDH, alkaline phosphatase, creatinine
- Before each treatment: CBC & diff, platelets, creatinine (creatinine before each CARBOplatin treatment only)
- If clinically indicated: bilirubin, ALT, GGT, alkaline phosphatase, urea, creatinine, MUGA scan or echocardiogram

**PREMEDICATIONS:**

- Antiemetic protocol for highly emetogenic chemotherapy (see protocol [SCNAUSEA](#))

**TREATMENT:**

| Drug                      | Dose                         | BC Cancer Administration Guideline     |
|---------------------------|------------------------------|--|
| PACLitaxel NAB (ABRAXANE) | 260 mg/m <sup>2</sup>        | IV over 30 minutes*                    |
| CARBOplatin               | AUC 6 or 5 or 4 x (GFR + 25) | IV in 100 to 250 mL NS over 30 minutes |

\*in empty sterile bags and tubing with **15** micron filter; no specific material required for bag or tubing

- PACLitaxel NAB and CARBOplatin to be given every 21 days to complete total number of cycles in original BRLACTWAC protocol, followed by
- Four consecutive cycles of DOXOrubicin and cyclophosphamide to start 21 days after final cycle of PACLitaxel NAB and CARBOplatin

| Drug             | Dose                  | BC Cancer Administration Guideline               |
|------------------|-----------------------|--|
| DOXOrubicin      | 60 mg/m <sup>2</sup>  | IV push  |
| cyclophosphamide | 600 mg/m <sup>2</sup> | IV in 100 to 250 mL NS over 20 minutes to 1 hour |

- Repeat every 21 days for 4 cycles

Measured GFR (e.g. nuclear renogram) is preferred whenever feasible, *particularly* in circumstances of co-morbidity that could affect renal function (third-space fluid accumulations, hypoproteinemia, potentially inadequate fluid intake, etc.). The lab

reported GFR (MDRD formula) may be used as an alternative to the Cockcroft-Gault estimate of GFR; the estimated GFR reported by the lab or calculated using the Cockcroft-Gault equation should be capped at 125 mL/min when it is used to calculate the initial CARBOplatin dose. When a nuclear renogram is available, this clearance would take precedence.

Cockcroft-Gault Formula

$$\text{GFR} = \frac{1.04 \times (140 - \text{age in years}) \times \text{wt (kg)}}{\text{serum creatinine (micromol/L)}}$$

Note: The same method of estimation should be used throughout the treatment course (i.e. if lab reported GFR was used initially, this should be used for dosing in all subsequent cycles and not the Cockcroft-Gault estimate).

**DOSE MODIFICATIONS:**

**1. Hematological**

For cycles of PACLitaxel NAB and CARBOplatin only:

| ANC (x 10 <sup>9</sup> /L)   |     | Platelets (x 10 <sup>9</sup> /L) | PACLitaxel NAB Dose  | CARBOplatin Dose   |
|------------------------------|-----|----------------------------------|--|--|
| greater than or equal to 1.5 | and | greater than or equal to 100     | 100% (260 mg/m <sup>2</sup> )  | 100%   |
| 1.0 to less than 1.5         | and | greater than or equal to 100     | 220 mg/m <sup>2</sup>  | 75%  |
| less than 1.0                | or  | less than 100                    | delay until ANC greater than or equal to 1.5 and platelets greater than or equal to 100 then consider giving 220 mg/m <sup>2</sup> | delay* until ANC greater than or equal to 1.5 and platelets greater than or equal to 100 then give 75% |

\*If repeated delays or dose reductions, consider reducing CARBOplatin to AUC of 5 from 6, or 4 from 5

**For cycles of DOXOrubicin and cyclophosphamide only:**

| ANC (x10 <sup>9</sup> /L)    |     | Platelets (x10 <sup>9</sup> /L) | Dose (both drugs) |
|------------------------------|-----|---------------------------------|-------------------|
| Greater than or equal to 1.5 | and | Greater than or equal to 90     | 100%              |
| 1.0 to less than 1.5         | or  | 70 to less than 90              | 75%               |
| Less than 1.0                | or  | Less than 70                    | Delay             |

**2. Febrile Neutropenia: PACLitaxel NAB**

|                     | 1 <sup>st</sup> Occurrence  | 2 <sup>nd</sup> Occurrence  |
|---------------------|---|---|
| Febrile Neutropenia | Delay until recovery (ANC greater than or equal to 1.5 x 10 <sup>9</sup> /L and platelets greater than or equal to 100 x 10 <sup>9</sup> /L), then dose reduce to <b>220 mg/m<sup>2</sup>**</b> | Delay until recovery (ANC greater than or equal to 1.5 x 10 <sup>9</sup> /L and platelets greater than or equal to 100 x 10 <sup>9</sup> /L), then dose reduce to <b>180 mg/m<sup>2</sup>**</b> |

\*\*Dose reductions should be maintained for subsequent cycles and not re-escalated

**3. Hepatic Dysfunction**

**For the cycles containing PACLitaxel NAB:**

| ALT or AST                     |        | Bilirubin   | PACLitaxel NAB only |
|--------------------------------|--------|---|---------------------|
| Less than or equal to 10 x ULN | and    | Greater than 1 to less than or equal to 1.5 x ULN | 100%                |
| Less than or equal to 10 x ULN | and/or | Greater than 1.5 to less than or equal to 5 x ULN | 80%*                |
| Greater than 10 x ULN          | or     | Greater than 5 x ULN                              | Hold                |

\* may re-escalate dose if hepatic function normalizes and reduced dose is tolerated for at least 2 cycles

**For the cycles containing DOXOrubicin:**

| <b>ALT or AST</b>    |    | <b>Bilirubin<br/>(micromol/L)</b> | <b>Dose</b>       |
|----------------------|----|-----------------------------------|-------------------|
| 2 to 3 x ULN         |    | -                                 | 75%               |
| greater than 3 x ULN | or | 20 to 51                          | 50%               |
| -                    |    | 51 to 85                          | 25%               |
| -                    |    | greater than 85                   | Do not administer |

4. **Renal dysfunction:** No modification is required for PACLitaxel NAB in mild to moderate renal impairment. PACLitaxel NAB has not been studied in patients with creatinine clearance less than 30 mL/min.

If significant increase (greater than 20% or rises above the upper limit of normal) in creatinine, recheck/recalculate GFR and recalculate CARBOplatin dose using new GFR.

Dose modification may be required for cyclophosphamide. Refer to BC Cancer Drug Manual.

## 5. Sensory Neuropathy- PACLitaxel NAB

| Grade | Toxicity   | Dose – 1 <sup>st</sup> Occurrence  | Dose – 2 <sup>nd</sup> Occurrence  |
|-------|--|--|--|
| 1     | Asymptomatic; loss of deep tendon reflexes or paresthesia (including tingling) but not interfering with function       | Maintain dose  | Maintain dose  |
| 2     | Sensory alteration or paresthesia (including tingling) but not interfering with function, but not interfering with ADL | Maintain dose  | Maintain dose  |
| 3     | Sensory alteration or paresthesia interfering with ADL   | Reduce dose to 220 mg/m <sup>2</sup> ** Consider holding treatment until resolved to grade 2   | Reduce dose to 180 mg/m <sup>2</sup> ** Consider holding treatment until resolved to grade 2   |
| 4     | Disabling  | Hold treatment until resolved to grade 2, then reduce dose to 220 mg/m <sup>2</sup> ** or discontinue further treatment at the discretion of physician | Hold treatment until resolved to grade 2, then reduce dose to 180 mg/m <sup>2</sup> ** or discontinue further treatment at the discretion of physician |

\*\*Dose reductions should be maintained for subsequent cycles and not re-escalated.

**6. Arthralgia and/or myalgia:** If arthralgia and/or myalgia from PACLitaxel NAB of grade 2 (moderate) or higher is not relieved by adequate doses of NSAIDs or acetaminophen with codeine (e.g., **TYLENOL #3®**), a limited number of studies report a possible therapeutic benefit using:

- predniSONE 10 mg PO bid x 5 days starting 24 hours post-PACLitaxel NAB
- Gabapentin 300 mg PO on day before chemotherapy, 300 mg bid on treatment day, then 300 mg tid x 7 to 10 days

If arthralgia and/or myalgia persist, reduce subsequent PACLitaxel NAB doses to 220 mg/m<sup>2</sup>.

## PRECAUTIONS:

1. An albumin form of PACLitaxel may substantially affect a drug's functional properties relative to those of drug in solution. **Do not** substitute with or for other PACLitaxel formulations.
2. **Extravasation:** DOXOrubicin and PACLitaxel NAB cause pain and tissue necrosis (rarely for PACLitaxel NAB) if extravasated. Refer to BC Cancer Extravasation Guidelines.
3. **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated aggressively.
4. **Hypersensitivity:** Reactions to CARBOplatin may occur. Refer to BC Cancer Hypersensitivity Guidelines.
5. **Cardiac toxicity** has been reported rarely while patients receive PACLitaxel NAB. Severe cardiovascular events (3%), including chest pain, cardiac arrest, supraventricular tachycardia, edema, thrombosis, pulmonary thromboembolism, pulmonary emboli, and hypertension.
6. **Cardiac Toxicity:** DOXOrubicin is cardiotoxic and must be used with caution in patients with cardiac dysfunction. Cardiac assessment recommended once cumulative dose reaches 300 mg/m<sup>2</sup> (see BC Cancer Drug Manual)
7. **Drug interactions:** PACLitaxel NAB is metabolized by CYP2C8 and CYP3A4; caution should be exercised when administering with drugs which are CYP2C8 or CYP3A4 inducers or inhibitors.
8. **Theoretical risk of viral disease transmission**, due to human albumin component, is extremely remote.

**Call Dr. Angela Chan or tumour group delegate at 604-877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.**

## References

1. Sánchez-Muñoz A, Jiménez B, García-Tapiador A, et al. Cross-sensitivity between taxanes in patients with breast cancer. *Clin Transl Oncol*. 2011 Dec;13(12):904-6.
2. Gianni L, Mansutti M, Anton A, et al. Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial. *JAMA Oncol*. 2018 Mar 1;4(3):302-308.
3. Untch M, Jackisch C, Schneeweiss A, et al. German Breast Group (GBG); Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) Investigators. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. *Lancet Oncol*. 2016 Mar;17(3):345-356.
4. Yuan Y, Lee JS, Yost SE, et al. Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer. *Oncologist*. 2021 Mar;26(3):e382-e393.
5. Brufsky A. *nab*-Paclitaxel for the treatment of breast cancer: an update across treatment settings. *Exp Hematol Oncol*. 2017 Mar 22;6:7.